← Leaderboards
James David Talton
Nanotherapeutics, Inc.
$15,179,333
Attributed
$15,179,333
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.4M · FY2005–10$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$15,179,333 · 5
By mechanism
N01$14,171,215 · 2
R01$812,118 · 1
N43$98,000 · 1
R43$98,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Nanotherapeutics, Inc.
Same institution · by research overlap
- Robert House$3,149,878
- James Talton$155,864
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionAlveolar MacrophagesAnimalsAntitubercular AgentsBiomedical Equipment DevelopmentBiosensor DeviceBioterrorism /Chemical WarfareBreath TestsCandidate SelectionChelationCidofovirDrug Delivery SystemsDrug DevelopmentDrug FormulationsDrug Screening /EvaluationFallsHigh Performance Liquid ChromatographyInhalation Drug AdministrationLaboratory MouseLeadMycobacterium TuberculosisNanotechnologyPolymersPowder Dose Form
Grant awards (6)
CIDOFOVIR FORMULATION FOR POSTEXPOSURE TREATMENT$6,431,950
N01 · FY2010 · AI · contact PI
CIDOFOVIR FORMULATION FOR POSTEXPOSURE TREATMENT$6,420,503
N01 · FY2009 · AI · contact PI
DEVELOPMENT OF IMPROVED DTPA FOR RADIONUCLIDE CHELATION$1,318,762
N01 · FY2007 · AI · contact PI
Inhaled Aminoglycoside Formulafor Plague and Tularemia$812,118
R01 · FY2005 · AI
PATIENT COMPLIANCE BREATH FEEDBACK SYSTEM - SBIR PHASE I$98,000
N43 · FY2000 · AA
DRY POWDER COATINGS FOR IMPROVED TUBERCULOSIS THERAPIES$98,000
R43 · FY2000 · AI